COMT inhibitors: management of Parkinson's disease.
D000978:Antiparkinson Agents / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D001577:Benzophenones / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D001921:Brain / Q000378:metabolism; D065098:Catechol O-Methyltransferase Inhibitors; D002396:Catechols / Q000493:pharmacokinetics / Q000494:pharmacology* / Q000627:therapeutic use*; D006801:Humans; D009570:Nitriles; D009596:Nitrophenols; D010300:Parkinson Disease / Q000188:drug therapy*; D011596:Psychomotor Disorders / Q000517:prevention & control; D016032:Randomized Controlled Trials as Topic; D000077867:Tolcapone
D000978:Antiparkinson Agents; D001577:Benzophenones; D065098:Catechol O-Methyltransferase Inhibitors; D002396:Catechols; D009570:Nitriles; D009596:Nitrophenols; C071192:entacapone; D000077867:Tolcapone